Tregs appear to be slightly different from common CD4+ T cells, as they correlate with poor prognosis in STS (149) and HCC (138) patients and positive outcomes in HNSCC (147) and bladder cancer (140) patients. The gene discussed is CD4; the disease is hepatocellular carcinoma.